Chiltern Early Phase: Fully Integrated and Business Ready

LONDON, Aug. 27 /PRNewswire/ -- Following the successful acquisition of
Drug Development Solutions ('DDS') in February, Chiltern, a leading contract
research organization, announced today that it has fully integrated its two
early Phase units into a single operation branded as Chiltern Early Phase.
Chiltern Early Phase is providing high quality early phase services for
the pharmaceutical industry via its two well established units in Slough (just
outside of London) and Dundee, Scotland. With a total of 72 high care beds, 42
of which are based at Ninewells Hospital in Dundee, Chiltern Early Phase can
cover all therapeutic areas and all types of clinical pharmacology studies,
with specialization in First Time in Man, drug photosensitivity, drug-drug
interaction, Japanese bridging and vaccine studies.
Glenn Kerkhof, Chiltern's Chief Executive Officer said, "When we created
Chiltern Early Phase, our vision was to develop a brand that would be
synonymous with quality and service excellence. We now have the team,
organization and facilities to deliver on this vision and provide a truly
expert Early Phase service at reasonable cost."
Dr Brian Sanderson, Medical Director of Chiltern Early Phase commented, "I
am delighted to see the integration completed so thoroughly and ahead of
schedule. We are now looking to build on our units' long histories of good
science and medicine, both in the areas where we have traditionally been
strong but also in new areas of specialization such as diabetes and
cardiovascular medicine. We are also looking forward to forging academic links
to provide specialist studies involving new biomarkers."
About Chiltern:
Established in 1982, Chiltern is a leading global Contract Research
Organization with extensive experience conducting and staffing international
Phase I to Phase IV clinical trials across a broad therapeutic range for a
wide variety of clients. Chiltern employs over 1,250 people located in 23
offices throughout Europe, the Americas and Asia. Chiltern provides services
including Early Phase, Global Clinical Development, Late Phase, Biometrics,
Medical and Regulatory Affairs and Resourcing Solutions.
For More Information Contact:

Catherine Lemercier
Chiltern International, Inc.
2111 Palomar Airport Road
Suite 200
Carlsbad
CA 92011
USA
Tel: 1 (760) 707 5025
Fax: 1 (760) 707 5022
Email: Catherine.Lemercier@chiltern.com

Richard Baptista
Chiltern International Ltd.
171 Bath Road
Slough
Berkshire
SL1 4AA
UNITED KINGDOM
Tel: 44 (0) 1753 512 000
Fax: 44 (0) 1753 511 116
Email: Richard.Baptista@chiltern.com

SOURCE Chiltern

Catherine Lemercier of Chiltern International, Inc., +1-760-707-5025, fax,
+1-760-707-5022, Catherine.Lemercier@chiltern.com, or Richard Baptista of
Chiltern International Ltd., 44 0 1753 512 000, fax, 44 0 1753 511 116,
Richard.Baptista@chiltern.com